<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04997941</url>
  </required_header>
  <id_info>
    <org_study_id>MORE-T trial</org_study_id>
    <nct_id>NCT04997941</nct_id>
  </id_info>
  <brief_title>Higher Dose Preoperative taMOxifen in Premenopausal bREast Cancer Patients</brief_title>
  <acronym>MORE-T</acronym>
  <official_title>Higher Dose taMOxifen in Premenopausal bREast Cancer Patients: a preoperaTive Window Trial (MORE-T Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      MORE-T trial is designed to investigate the effect of Tamoxifen 40mg (vs. Tamoxifen 20mg) for&#xD;
      2wks in presurgical setting.&#xD;
&#xD;
      The greater reduction in Ki-67 might be observed in Tamoxifen 40mg arm compared to the&#xD;
      Tamoxifen 20mg arm.&#xD;
&#xD;
      Open Label, Phase 2, Randomized with 1:1 allocation&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tamoxifen&#xD;
&#xD;
        -  Selective estrogen receptor modulator&#xD;
&#xD;
        -  It has been the main endocrine treatment for decades&#xD;
&#xD;
        -  Tamoxifen is a major endocrine treatment option, particularly for women who still have a&#xD;
           significant ovarian estrogenic activity that cannot be controlled by aromatase&#xD;
           inhibitors.&#xD;
&#xD;
        -  The prospective clinical trials have shown that tamoxifen 20mg has comparable efficacy&#xD;
           against tamoxifen 40mg with fewer toxicities in breast cancer patients. However, most of&#xD;
           the trials comparing tamoxifen 20mg and 40mg were done in postmenopausal women.&#xD;
&#xD;
        -  Previous studies have suggested that the higher dose of tamoxifen can induce higher&#xD;
           serum levels of the drugs, and increasing tamoxifen dose up to 40mg can induce clinical&#xD;
           responses in tumors resistant to 20mg of tamoxifen. A recent prospective trial&#xD;
           demonstrated that increasing the dose of tamoxifen from 20 mg to 40 mg can compensate&#xD;
           for the reduced endoxifen level in intermediate or poor metabolizer tamoxifen&#xD;
           metabolizers based on CYP2D6 genotyping.&#xD;
&#xD;
      Ki-67&#xD;
&#xD;
        -  Ki-67 antigen, a nuclear antigen, and marker of cell proliferation, is expressed during&#xD;
           all cell-cycle phases except for G0, with levels peaking during mitosis.&#xD;
&#xD;
        -  Reduction in Ki67 expression is reported to correlate with treatment response to&#xD;
           endocrine therapy in ER+ breast cancer, and Ki-67 in short-term neoadjuvant studies has&#xD;
           been shown to predict outcome in long-term adjuvant trials.&#xD;
&#xD;
      As the investigators have a higher proportion of young aged, premenopausal breast cancer&#xD;
      patients in Korea, the investigators had an opportunity to examine the prognostic impact of&#xD;
      young age in breast cancer recurrences and survivals. The institutional database and the&#xD;
      Korean nationwide breast cancer registry data have all shown that the poor prognostic effect&#xD;
      of a young age was exclusively seen in women with hormone receptor-positive breast cancers,&#xD;
      and the effect was potentially due to the resistance to the tamoxifen. As therapeutic options&#xD;
      diversify, studies on factors predictive of sensitivity to various endocrine therapies are&#xD;
      needed to help select the appropriate treatment for young premenopausal breast cancer&#xD;
      patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 13, 2021</start_date>
  <completion_date type="Anticipated">March 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Ki-67 level</measure>
    <time_frame>After 14-day of tamoxifen treatment</time_frame>
    <description>Change in Ki67 (percentage of positive tumor cells tested by immunohistochemistry [IHC] - digital Image Analysis ) after a 14-day treatment period compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Ki67 according to CYP2D6 genotyping</measure>
    <time_frame>After 14-day of tamoxifen treatment</time_frame>
    <description>Change in Ki67 (percentage of positive tumor cells tested by immunohistochemistry [IHC]) after a 14-day treatment period compared to baseline according to CYP2D6 genotyping.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of participants with relative decrease from baseline of Ki-67 ≥50%</measure>
    <time_frame>After 14-day of tamoxifen treatment</time_frame>
    <description>The proportion of participants with relative decrease from baseline of Ki-67 (% positive tumor cells) ≥50%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE</measure>
    <time_frame>After 14-day of tamoxifen treatment</time_frame>
    <description>Adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAE</measure>
    <time_frame>After 14-day of tamoxifen treatment</time_frame>
    <description>Serious adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEPI (Preoperative Endocrine Prognostic Index) score</measure>
    <time_frame>After 14-day of tamoxifen treatment</time_frame>
    <description>The PEPI score (ranged 0 to 12, lower score mean a better outcome) is the sum of the risk points of the pathological tumor (pT) stage, the pathological node (pN) stage, Ki67 levels and ER status (Allred score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RFS</measure>
    <time_frame>5 years</time_frame>
    <description>Relapse-free survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>5 years</time_frame>
    <description>Overall survival rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">238</enrollment>
  <condition>Premenopausal Breast Cancer</condition>
  <condition>Hormone Receptor-positive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Tamoxifen 40mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tamoxifen 20mg b.i.d - Participants will be treated for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tamoxifen 20mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tamoxifen 10mg b.i.d - Participants will be treated for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen Oral Product</intervention_name>
    <description>Experimental arm will have tamoxifen 40mg and active comparator arm will have tamoxifen 20mg for 14 days.</description>
    <arm_group_label>Tamoxifen 20mg</arm_group_label>
    <arm_group_label>Tamoxifen 40mg</arm_group_label>
    <other_name>Tamoxifen 40mg vs. 20mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Assessment of Ki-67</intervention_name>
    <description>Paired biopsies (before and after tamoxifen therapy) will be required for the assessment of Ki-67.</description>
    <arm_group_label>Tamoxifen 20mg</arm_group_label>
    <arm_group_label>Tamoxifen 40mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>The surgery date should be fixed before randomization. The surgery is to be performed within 1 day after the last dose of study treatment.</description>
    <arm_group_label>Tamoxifen 20mg</arm_group_label>
    <arm_group_label>Tamoxifen 40mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histopathologically and immunohistochemically confirmed ER+ and HER2- Premenopausal BC&#xD;
             patients&#xD;
&#xD;
          2. Tumor size &gt;0.5cm on USG&#xD;
&#xD;
          3. Stage I-IIIA BC and planned curative surgery&#xD;
&#xD;
          4. ECOG 0-2&#xD;
&#xD;
          5. Patients with adequate bone marrow function&#xD;
&#xD;
             - Hemoglobin 10 g/dL, ANC 1,500/mm3, Plt 100,000/mm3&#xD;
&#xD;
          6. Patients with adequate kidney function&#xD;
&#xD;
             - serum Cr ≤ 1.5 mg/dL&#xD;
&#xD;
          7. Patients with adequate liver function&#xD;
&#xD;
               -  Bilirubin: ≤ 1.5 times of upper normal limit&#xD;
&#xD;
               -  AST/ALT: ≤ 1.5 times of upper normal limit&#xD;
&#xD;
               -  Alkaline phosphatase: ≤ 1.5 times of upper normal limit&#xD;
&#xD;
          8. Patients who decided to voluntarily participate in this trial with written informed&#xD;
             consent&#xD;
&#xD;
          9. Premenopausal women : women who has not removed both ovaries, women who had menses in&#xD;
             recent 1 year and FSH level is less than 30mIU/ml&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous history of ipsilateral invasive breast cancer, in situ lesion&#xD;
&#xD;
          2. Previous history of chemotherapy or endocrine therapy on contralateral BC for the past&#xD;
             2 years&#xD;
&#xD;
          3. Patients who has distant metastasis&#xD;
&#xD;
          4. Patients who is pregnant or breastfeeding&#xD;
&#xD;
          5. Hormon receptor negative BC&#xD;
&#xD;
          6. Her-2 positive BC&#xD;
&#xD;
          7. Diagnosed pituitary adenoma&#xD;
&#xD;
          8. Women who has endometriosis, uterine myoma, unknown vaginal bleeding&#xD;
&#xD;
          9. Inability to understand and willingness to sign a written informed consent&#xD;
&#xD;
         10. Patients with endometriosis, uterine fibroids, or unexplained vaginal bleeding&#xD;
&#xD;
         11. Patients with a history of bleeding constitution, coagulopathy, or thromboembolism&#xD;
&#xD;
         12. Patients who have administered a CYP3A inhibitor or inducer, CYP2D6 inhibitor, etc.&#xD;
             within 4 weeks prior to randomization&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>48 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyeong-Gon Moon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hong-Kyu Kim</last_name>
    <phone>+82-2-2072-2817</phone>
    <email>hkkim4592@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hyeong-Gon Moon</last_name>
    <phone>+82-2-2072-2634</phone>
    <email>moonhgsurgi@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Hyeong-Gon Moon, MD</last_name>
      <phone>02-2072-2634</phone>
      <email>moonhgsurgi@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Hong-Kyu Kim</last_name>
      <phone>02-2072-2817</phone>
      <email>hkkim4592@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 23, 2021</study_first_submitted>
  <study_first_submitted_qc>August 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Hyeong-Gon Moon</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Premenopausal Breast Cancer</keyword>
  <keyword>Ki-67</keyword>
  <keyword>Hormone Receptor-positive Breast Cancer</keyword>
  <keyword>Tamoxifen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

